Bliss GVS Pharma consolidated net profit declines 13.80% in the December 2024 quarter
29 - Jan - 2025 12:00 | 92 days ago
Net profit of Bliss GVS Pharma declined 13.80% to Rs 23.80 crore in the quarter ended December 2024 as against Rs 27.61 crore during the previous quarter ended December 2023. Sales rose 4.83% to Rs 210.42 crore in the quarter ended December 2024 as against Rs 200.72 crore during the previous quarter ended December 2023.
Bliss GVS Pharma allots 34,250 equity shares under ESOP
06 - Dec - 2024 12:00 | 146 days ago
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-.
Bliss GVS Pharma allots 34,250 equity shares under ESOP
06 - Dec - 2024 12:00 | 146 days ago
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-.
Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority
25 - Nov - 2024 12:00 | 157 days ago
In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR).
The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities.
Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind.
The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24.
Bliss GVS Pharma consolidated net profit declines 13.80% in the December 2024 quarter
29 - Jan - 2025 12:00 | 92 days ago
Net profit of Bliss GVS Pharma declined 13.80% to Rs 23.80 crore in the quarter ended December 2024 as against Rs 27.61 crore during the previous quarter ended December 2023. Sales rose 4.83% to Rs 210.42 crore in the quarter ended December 2024 as against Rs 200.72 crore during the previous quarter ended December 2023.
Bliss GVS Pharma allots 34,250 equity shares under ESOP
06 - Dec - 2024 12:00 | 146 days ago
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-.
Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority
25 - Nov - 2024 12:00 | 157 days ago
In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR).
The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities.
Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind.
The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24.
Bliss GVS Pharma consolidated net profit declines 13.80% in the December 2024 quarter
29 - Jan - 2025 12:00 | 92 days ago
Net profit of Bliss GVS Pharma declined 13.80% to Rs 23.80 crore in the quarter ended December 2024 as against Rs 27.61 crore during the previous quarter ended December 2023. Sales rose 4.83% to Rs 210.42 crore in the quarter ended December 2024 as against Rs 200.72 crore during the previous quarter ended December 2023.
Bliss GVS Pharma allots 34,250 equity shares under ESOP
06 - Dec - 2024 12:00 | 146 days ago
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-.
Bliss GVS Pharma allots 34,250 equity shares under ESOP
06 - Dec - 2024 12:00 | 146 days ago
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-.
Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority
25 - Nov - 2024 12:00 | 157 days ago
In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR).
The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities.
Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind.
The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24.
